The Therapeutic Effects of Semaglutide in Congenital Linear Scleroderma.

Chen H, Elhawi M, Tarbox M

Cureus25 Jul 2025Cited by 2 (Europe PMC)

PMID40861533PMCIDPMC12376079DOI10.7759/cureus.88725PepBankPUB-40861533

Summary

Congenital linear scleroderma (CLS) is a rare connective tissue disorder characterized by unilateral linear induration that can lead to restricted mobility and limb deformities. Various treatments have been proposed, including D-penicillamine, phototherapy, oral vitamin D, and immunosuppressants such as methotrexate (MTX), cyclosporine, and interleukin-6 (IL-6) inhibitors. We present the case of a 14-year-old female patient with refractory CLS, whose condition continued to worsen despite treatment with tocilizumab, mycophenolate mofetil (MMF), and MTX. She was subsequently started on a glucagon-like peptide-1 (GLP-1) receptor agonist and began to experience improved mobility in her left arm and decreased skin hardening. To our knowledge, this is the first reported case suggesting the potential role of GLP-1 receptor agonists in slowing the progression of localized scleroderma, possibly due to their anti-fibrotic and anti-inflammatory effects.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanCase report or seriesEfficacy outcome
In a 14-year-old female patient with refractory congenital linear scleroderma, semaglutide was followed by improved mobility in the left arm.
In plain wordsA 14-year-old girl with a rare skin condition had better left arm movement after starting semaglutide; one case cannot show cause.
Peptide
Semaglutide
Outcome
IncreaseMobility of left arm
Study
n = 1
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
She was subsequently started on a glucagon-like peptide-1 (GLP-1) receptor agonist and began to experience improved mobility in her left arm and decreased skin hardening.
2 context sentences(design, population, supporting numbers)
Title · context
The Therapeutic Effects of Semaglutide in Congenital Linear Scleroderma.
Summary · context
We present the case of a 14-year-old female patient with refractory CLS, whose condition continued to worsen despite treatment with tocilizumab, mycophenolate mofetil (MMF), and MTX.
Show in the study text Report a problemFND-4086153301
02HumanCase report or seriesEfficacy outcome
In a 14-year-old female patient with refractory congenital linear scleroderma, semaglutide was followed by decreased skin hardening.
In plain wordsA 14-year-old girl with a rare skin condition had less skin hardening after starting semaglutide; one case cannot show cause.
Peptide
Semaglutide
Outcome
DecreaseSkin hardening
Study
n = 1
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
She was subsequently started on a glucagon-like peptide-1 (GLP-1) receptor agonist and began to experience improved mobility in her left arm and decreased skin hardening.
2 context sentences(design, population, supporting numbers)
Title · context
The Therapeutic Effects of Semaglutide in Congenital Linear Scleroderma.
Summary · context
We present the case of a 14-year-old female patient with refractory CLS, whose condition continued to worsen despite treatment with tocilizumab, mycophenolate mofetil (MMF), and MTX.
Show in the study text Report a problemFND-4086153302

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.